Motor fluctuations — the unpredictable cycling between good mobility and frozen immobility — represent one of the most disabling aspects of long-term Parkinson's disease management. Existing dopamine agonists help extend functional periods but carry well-documented risks of impulse control disorders, excessive daytime sleepiness, and cardiac complications tied to D2/D3 receptor activation. A compound that selectively targets D1/D5 receptors could fundamentally reshape the adjunctive therapy landscape for the estimated one million Americans living with Parkinson's.
The TEMPO-3 trial, a phase 3 double-blind, placebo-controlled study conducted across 148 sites in 14 countries between 2020 and 2024, randomized adults with Parkinson's experiencing motor fluctuations on stable levodopa (≥400 mg daily) to flexible-dose tavapadon (5–15 mg once daily) or placebo for 27 weeks. The primary endpoint was change in total daily "good on-time" — periods of smooth, functional mobility without troublesome dyskinesia — from baseline to week 26. A key secondary endpoint assessed off-time reduction, measuring hours lost to motor deterioration.
The D1/D5 receptor selectivity of tavapadon is pharmacologically meaningful and underexplored in clinical practice. D1 receptors are enriched in the direct striatal pathway, which promotes movement initiation, whereas D2/D3 receptors modulate the indirect pathway. Most current agonists — pramipexole, ropinirole, rotigotine — preferentially activate D2/D3, which explains both their efficacy and their side-effect burden. Tavapadon's mechanism represents a decades-old theoretical target finally reaching phase 3 validation. Prior TEMPO-1 and TEMPO-2 monotherapy trials showed early promise in de novo patients, making TEMPO-3 a critical test of adjunctive utility in a more advanced, fluctuating population. The multinational design and large site network strengthen external validity. Key limitations include the 27-week observation window — insufficient to assess whether D1/D5 selectivity confers long-term advantages in dyskinesia development — and whether flexible dosing introduces confounding. Regulatory significance is high if efficacy endpoints were met, as tavapadon could represent the first approved D1/D5-selective oral agent for Parkinson's, a genuinely novel mechanistic category.